FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2159780218> ?p ?o ?g. }

• W2159780218 endingPage "31" @default.
• W2159780218 startingPage "27" @default.
• W2159780218 abstract "Objectives To determine whether there is an oncologic benefit of adjuvant bacillus Calmette Guérin (BCG) after resection of upper tract transitional cell carcinoma (UTTCC). Methods A total of 133 renal units (RU) treated by percutaneous resection for UTTCC between 1985 and 2005 were retrospectively analyzed. Forty-four RU were excluded because of carcinoma in situ, high grade/stage, metastatic disease present at initial presentation, and/or the patient could tolerate loss of RU. Eighty-nine RU treated primarily by percutaneous resection were then analyzed. Fifty RU received adjuvant BCG therapy 2 weeks after endoscopic management for a total of 6 courses. Recurrence was defined as a positive biopsy result after the third-look nephroscopy. Progression of disease was assessed at time of recurrence and defined as an increase in grade/stage of disease. Results Mean age (± SD) of 89 RU was 70.9 ± 11.1 years. Overall follow-up was 61.1 + 54.8 months. Grade distribution was 56.2% (50 of 89) and 43.8% (39 of 89) for low- and high-grade disease, respectively. There was no statistical difference with regard to tumor grade or stage between treated and nontreated groups (P > .05). Recurrence, time to recurrence, and progression of disease among RU treated with BCG were subselected by grade and compared with the corresponding nontreated group. Statistical significance between any of the treated and nontreated groups was not demonstrated (P > .05). Conclusions Our data demonstrate that there is no overall oncologic benefit in the administration of adjuvant BCG with regard to disease recurrence, interval to recurrence, and progression of disease in the treatment of UTTCC. To determine whether there is an oncologic benefit of adjuvant bacillus Calmette Guérin (BCG) after resection of upper tract transitional cell carcinoma (UTTCC). A total of 133 renal units (RU) treated by percutaneous resection for UTTCC between 1985 and 2005 were retrospectively analyzed. Forty-four RU were excluded because of carcinoma in situ, high grade/stage, metastatic disease present at initial presentation, and/or the patient could tolerate loss of RU. Eighty-nine RU treated primarily by percutaneous resection were then analyzed. Fifty RU received adjuvant BCG therapy 2 weeks after endoscopic management for a total of 6 courses. Recurrence was defined as a positive biopsy result after the third-look nephroscopy. Progression of disease was assessed at time of recurrence and defined as an increase in grade/stage of disease. Mean age (± SD) of 89 RU was 70.9 ± 11.1 years. Overall follow-up was 61.1 + 54.8 months. Grade distribution was 56.2% (50 of 89) and 43.8% (39 of 89) for low- and high-grade disease, respectively. There was no statistical difference with regard to tumor grade or stage between treated and nontreated groups (P > .05). Recurrence, time to recurrence, and progression of disease among RU treated with BCG were subselected by grade and compared with the corresponding nontreated group. Statistical significance between any of the treated and nontreated groups was not demonstrated (P > .05). Our data demonstrate that there is no overall oncologic benefit in the administration of adjuvant BCG with regard to disease recurrence, interval to recurrence, and progression of disease in the treatment of UTTCC." @default.
• W2159780218 created "2016-06-24" @default.
• W2159780218 creator A5045356209 @default.
• W2159780218 creator A5046166302 @default.
• W2159780218 creator A5051067018 @default.
• W2159780218 creator A5054421376 @default.
• W2159780218 creator A5055473847 @default.
• W2159780218 creator A5069237613 @default.
• W2159780218 creator A5076091439 @default.
• W2159780218 creator A5087237633 @default.
• W2159780218 date "2009-01-01" @default.
• W2159780218 modified "2023-10-10" @default.
• W2159780218 title "A 20-Year Experience With Percutaneous Resection of Upper Tract Transitional Carcinoma: Is There an Oncologic Benefit With Adjuvant Bacillus Calmette Guérin Therapy?" @default.
• W2159780218 cites W1827138708 @default.
• W2159780218 cites W1965699223 @default.
• W2159780218 cites W2001360150 @default.
• W2159780218 cites W2043319711 @default.
• W2159780218 cites W2063425684 @default.
• W2159780218 cites W2069297249 @default.
• W2159780218 cites W2073194480 @default.
• W2159780218 cites W2079429669 @default.
• W2159780218 cites W2083785563 @default.
• W2159780218 cites W2105260028 @default.
• W2159780218 cites W2135674005 @default.
• W2159780218 cites W2142084667 @default.
• W2159780218 cites W2142232822 @default.
• W2159780218 cites W2407181252 @default.
• W2159780218 cites W2411318851 @default.
• W2159780218 cites W2889251303 @default.
• W2159780218 cites W41337129 @default.
• W2159780218 doi "https://doi.org/10.1016/j.urology.2008.06.026" @default.
• W2159780218 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18929398" @default.
• W2159780218 hasPublicationYear "2009" @default.
• W2159780218 type Work @default.
• W2159780218 sameAs 2159780218 @default.
• W2159780218 citedByCount "88" @default.
• W2159780218 countsByYear W21597802182012 @default.
• W2159780218 countsByYear W21597802182013 @default.
• W2159780218 countsByYear W21597802182014 @default.
• W2159780218 countsByYear W21597802182015 @default.
• W2159780218 countsByYear W21597802182016 @default.
• W2159780218 countsByYear W21597802182017 @default.
• W2159780218 countsByYear W21597802182018 @default.
• W2159780218 countsByYear W21597802182019 @default.
• W2159780218 countsByYear W21597802182020 @default.
• W2159780218 countsByYear W21597802182021 @default.
• W2159780218 countsByYear W21597802182022 @default.
• W2159780218 countsByYear W21597802182023 @default.
• W2159780218 crossrefType "journal-article" @default.
• W2159780218 hasAuthorship W2159780218A5045356209 @default.
• W2159780218 hasAuthorship W2159780218A5046166302 @default.
• W2159780218 hasAuthorship W2159780218A5051067018 @default.
• W2159780218 hasAuthorship W2159780218A5054421376 @default.
• W2159780218 hasAuthorship W2159780218A5055473847 @default.
• W2159780218 hasAuthorship W2159780218A5069237613 @default.
• W2159780218 hasAuthorship W2159780218A5076091439 @default.
• W2159780218 hasAuthorship W2159780218A5087237633 @default.
• W2159780218 hasConcept C126322002 @default.
• W2159780218 hasConcept C126894567 @default.
• W2159780218 hasConcept C141071460 @default.
• W2159780218 hasConcept C146357865 @default.
• W2159780218 hasConcept C151730666 @default.
• W2159780218 hasConcept C2775934546 @default.
• W2159780218 hasConcept C2776694085 @default.
• W2159780218 hasConcept C2777546739 @default.
• W2159780218 hasConcept C2777661416 @default.
• W2159780218 hasConcept C2777863537 @default.
• W2159780218 hasConcept C2777982462 @default.
• W2159780218 hasConcept C2780813298 @default.
• W2159780218 hasConcept C65409693 @default.
• W2159780218 hasConcept C71924100 @default.
• W2159780218 hasConcept C86803240 @default.
• W2159780218 hasConcept C90924648 @default.
• W2159780218 hasConceptScore W2159780218C126322002 @default.
• W2159780218 hasConceptScore W2159780218C126894567 @default.
• W2159780218 hasConceptScore W2159780218C141071460 @default.
• W2159780218 hasConceptScore W2159780218C146357865 @default.
• W2159780218 hasConceptScore W2159780218C151730666 @default.
• W2159780218 hasConceptScore W2159780218C2775934546 @default.
• W2159780218 hasConceptScore W2159780218C2776694085 @default.
• W2159780218 hasConceptScore W2159780218C2777546739 @default.
• W2159780218 hasConceptScore W2159780218C2777661416 @default.
• W2159780218 hasConceptScore W2159780218C2777863537 @default.
• W2159780218 hasConceptScore W2159780218C2777982462 @default.
• W2159780218 hasConceptScore W2159780218C2780813298 @default.
• W2159780218 hasConceptScore W2159780218C65409693 @default.
• W2159780218 hasConceptScore W2159780218C71924100 @default.
• W2159780218 hasConceptScore W2159780218C86803240 @default.
• W2159780218 hasConceptScore W2159780218C90924648 @default.
• W2159780218 hasIssue "1" @default.
• W2159780218 hasLocation W21597802181 @default.
• W2159780218 hasLocation W21597802182 @default.
• W2159780218 hasOpenAccess W2159780218 @default.
• W2159780218 hasPrimaryLocation W21597802181 @default.
• W2159780218 hasRelatedWork W2008451869 @default.
• W2159780218 hasRelatedWork W2033492984 @default.
• W2159780218 hasRelatedWork W2076007772 @default.
• W2159780218 hasRelatedWork W2349999257 @default.

• next